Will This Unknown Boston Biotech Make Present Surgical Techniques Obsolete?
by DrKSSMDPhD | October 5, 2014 6:04 pm
Dr. KSS Looks at clotting for the Irregulars
This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.
Source URL: https://www.stockgumshoe.com/2014/10/microblog-will-this-unknown-boston-biotech-make-present-surgical-techniques-obsolete/
Dr. KSS—-Welcome back. It just did not seem the same without you here. I added some more CTIX on the dip. Thanks for all the help
Glenn—-Your enthusiasm for CTIX has been contagious to me. Do not worry, i also do some reading on the company. I would never have anything negative to say here about anyone based on a stock’s performance. Thanks you also
Doc Kss what do you think of Brilacidin’s chances going after Crohns Disease,Ulcerative Colitis, and Inflammatory Bowel Disease?This study suggests it may.
http://immed.org/illness/autoimmune_illness_research.html
Cheers,Glenn
Doctor KSS..welcome home….Re: resonant medical names for new devices etc:
Any truth to the rumor that a vary famous, former R &B singer will be endorsing a new device to help in contamination protection.
I hear it’ll be known as the MOTOWN-ROSS SHIELD.
Blessings,
Ken
I want to thank everyone on this site for being so nice. I looked at the message board on yahoo finance today and was appalled at how rude people were to each other.
Totally uncalled for jeering and degrading remarks…maybe they were kidding but it didn’t seem so.
Alan, definitely with, not at. I had just read Kenny’s post, scrolled down and saw “snore”. Perfect timing, and too funny. I’ve come to look forward to your humor, and have respect for your advice. I don’t know much either about biotech investing but I can see good sense when I read it, and you always have that, and both served up with genuine kindness.
The both is your humor and your advice. And both are appreciated.
Dr KSS,
It would be great if you could attend Benitec’s AGM, but such a sacrifice in time for you. Is there any plan of action you would recommend us shareholders to take to effect positive change in the company? I have no faith in the board members finding courage to oust him, but one would think that large institutional shareholders should be fighting mad about now.
At this point, I hope and pray of simply regaining close to my original investment.
Remember DOC KSS was really the catalyst for Benitec here in the USA which drove the SP to over $2.00
He could also be the catalyst for tanking the stock which would force the change of CEO. This might be a more efficent way to get this going?
Too late for that Terje. Beni has bet us to that by tanking all on its own. 🙁
….. make that “beat us”…..
Dr.KSS: Is it possible to invest in STAT-3 silencing or other checkpoint related biotech? Your tweet is interesting!
Dr. KSS has a new article for comments at http://www.stockgumshoe.com/2014/10/microblog-the-gain-from-pain-mainly-explained-fire-walk-with-me/
SeeThruEquity Initiates Research Coverage on Arch Therapeutics with a Target Price of $1.50 http://www.baystreet.ca/viewarticle.aspx?id=422498
Looks like things might be heating up for ARTH …
Arch Therapuetics 2015 in Review
22 Press Releases in 2015
27 Press Releases in 2014
Dr. Terrence Norchi did Eight presentations in 2015
Net Cash Used in Operatons
2015 $ 4,239,386.00
2014 3,348,502.00
2013 1,434,620.00
_______________
$ 9,022,508.00
Cash Capital Raised
2013 Common Stock Sold $ 2,000,000.00
2014 Common Stock Sold $ 2,624,703.00
Note Payable $ 1,000,000.00
2015 Exercise of Warrants $ 3,600,000.00
Common Stock Sold $ 3,015,966.00
Convertible Note $ 750,000.00
___________________
Grand Total $ 12,990,669.00
1) Additional Cash required for full European and USA Human Clinical Trials $10 -14 Million (Note $ 12.990 million raised above)
2) The difference between the $ 9,022,508 and the $ 12,990,669 is the cash they have on hand at year end September 30, 2025 of $ 3.9 million
3) The $ 3,600,000 pertaining to the exercise of warrants resulted in 18 million shares being sold in the market as a result of warrant holder “blocker” provision. Sell shares owned in open market and use proceeds to exercise warrant.
4) 45% of the Series A warrants expiring 2/14/19 were exercised in fiscal year ending 9/30/15—
6 million shares times $.20 share and cashless exercise 1.756 million resulting in 686,801 being issued.